Search research articles
Contact Us
Filters
Showing results (161-170 of 288) with videos related to
Page
of 29
Sort By:
Urology
|
August 2, 2003
Prognostic significance of CA 125, CD44, and epithelial membrane antigen in renal cell carcinoma
A Bamias, M Chorti, C Deliveliotis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 18, 2003
Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study
K Zervas, M A Dimopoulos, E Hatzicharissi, et al.
Radiology
|
September 1, 1993
Waldenström macroglobulinemia: MR imaging of the spine and CT of the abdomen and pelvis
L A Moulopoulos, M A Dimopoulos, D G Varma, et al.
Leukemia
|
August 5, 2005
The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio
E Terpos, D Mihou, R Szydlo, et al.
Oncology
|
August 26, 1999
Outpatient treatment of neutropenic fever with oral antibiotics and granulocyte colony-stimulating factor
C Papadimitris, M A Dimopoulos, E Kostis, et al.
Urology
|
January 26, 2005
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment
E Efstathiou, G Bozas, A Kostakopoulos, et al.
Gynecologic Oncology
|
July 19, 2011
Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: a single institution experience
A Bamias, A Karadimou, N Soupos, et al.
Leukemia
|
September 5, 2008
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis
E Terpos, E Kastritis, M Roussou, et al.
Leukemia
|
July 6, 2012
The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma
M A Dimopoulos, M Roussou, M Gkotzamanidou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2004
Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group
A Bamias, Ch Deliveliotis, G Fountzilas, et al.
Page
of 29
Search research articles
Search
Showing results (161-170 of 288) with videos related to
Sort By:
Page
of 29
Urology
|
August 2, 2003
Prognostic significance of CA 125, CD44, and epithelial membrane antigen in renal cell carcinoma
A Bamias, M Chorti, C Deliveliotis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 18, 2003
Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study
K Zervas, M A Dimopoulos, E Hatzicharissi, et al.
Radiology
|
September 1, 1993
Waldenström macroglobulinemia: MR imaging of the spine and CT of the abdomen and pelvis
L A Moulopoulos, M A Dimopoulos, D G Varma, et al.
Leukemia
|
August 5, 2005
The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio
E Terpos, D Mihou, R Szydlo, et al.
Oncology
|
August 26, 1999
Outpatient treatment of neutropenic fever with oral antibiotics and granulocyte colony-stimulating factor
C Papadimitris, M A Dimopoulos, E Kostis, et al.
Urology
|
January 26, 2005
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment
E Efstathiou, G Bozas, A Kostakopoulos, et al.
Gynecologic Oncology
|
July 19, 2011
Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: a single institution experience
A Bamias, A Karadimou, N Soupos, et al.
Leukemia
|
September 5, 2008
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis
E Terpos, E Kastritis, M Roussou, et al.
Leukemia
|
July 6, 2012
The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma
M A Dimopoulos, M Roussou, M Gkotzamanidou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2004
Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group
A Bamias, Ch Deliveliotis, G Fountzilas, et al.
Page
of 29